Which has better valuation and earnings, OKYO or QNTM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is OKYO or QNTM more profitable?

OKYO Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Quantum Biopharma N/A -582.23% -184.20%

Does the media prefer OKYO or QNTM?

In the previous week, Quantum Biopharma had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 7 mentions for Quantum Biopharma and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.41 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer YARW or QNTM?

In the previous week, Yarrow Bioscience had 7 more articles in the media than Quantum Biopharma. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.41 beat Yarrow Bioscience's score of 0.37 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is QNTM or CTOR more profitable?

Citius Oncology's return on equity of -102.98% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Citius Oncology N/A -102.98% -43.49%

Do analysts prefer TELO or QNTM?

Quantum Biopharma has a consensus target price of $8.00, suggesting a potential upside of 129.23%. Given Quantum Biopharma's higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, TELO or QNTM?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is TELO or QNTM more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Quantum Biopharma N/A -582.23% -184.20%

Does the media favor TELO or QNTM?

In the previous week, Quantum Biopharma had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 7 mentions for Quantum Biopharma and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.62 beat Quantum Biopharma's score of 0.41 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SERA or QNTM?

In the previous week, Sera Prognostics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 10 mentions for Sera Prognostics and 7 mentions for Quantum Biopharma. Sera Prognostics' average media sentiment score of 0.44 beat Quantum Biopharma's score of 0.41 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Quantum Biopharma (QNTM) Competitors

$3.49 +0.03 (+0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$3.48 -0.01 (-0.29%)

As of 05:05 PM Eastern

Compare

QNTM vs. OKYO, YARW, CTOR, TELO, and SERA

Should you buy Quantum Biopharma stock or one of its competitors? Quantum Biopharma's main competitors and comparable companies include OKYO Pharma (OKYO), Yarrow Bioscience (YARW), Citius Oncology (CTOR), Telomir Pharmaceuticals (TELO), and Sera Prognostics (SERA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quantum Biopharma compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OKYO Pharma currently has a consensus price target of $5.67, indicating a potential upside of 322.89%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 129.23%. Given OKYO Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe OKYO Pharma is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

In the previous week, Quantum Biopharma had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 7 mentions for Quantum Biopharma and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.41 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Quantum Biopharma	N/A	-582.23%	-184.20%

OKYO Pharma has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Summary

OKYO Pharma beats Quantum Biopharma on 9 of the 11 factors compared between the two stocks.

How does Quantum Biopharma compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Yarrow Bioscience has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

In the previous week, Yarrow Bioscience had 7 more articles in the media than Quantum Biopharma. MarketBeat recorded 14 mentions for Yarrow Bioscience and 7 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.41 beat Yarrow Bioscience's score of 0.37 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Yarrow Bioscience currently has a consensus price target of $58.00, indicating a potential upside of 127.45%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 129.23%. Given Quantum Biopharma's higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quantum Biopharma has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	119.45	-$26.48M	-$14.64	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Quantum Biopharma has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

Yarrow Bioscience beats Quantum Biopharma on 8 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Citius Oncology?

Quantum Biopharma (NASDAQ:QNTM) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Citius Oncology's return on equity of -102.98% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Citius Oncology	N/A	-102.98%	-43.49%

Quantum Biopharma has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market.

In the previous week, Quantum Biopharma had 6 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for Quantum Biopharma and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.41 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Citius Oncology	Very Positive

Citius Oncology has higher revenue and earnings than Quantum Biopharma. Citius Oncology is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Citius Oncology	$7.11M	11.20	-$24.76M	-$0.47	N/A

Quantum Biopharma currently has a consensus target price of $8.00, suggesting a potential upside of 129.23%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 600.93%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Citius Oncology beats Quantum Biopharma on 12 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Quantum Biopharma has a consensus target price of $8.00, suggesting a potential upside of 129.23%. Given Quantum Biopharma's higher probable upside, analysts plainly believe Quantum Biopharma is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals' return on equity of -102.70% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Quantum Biopharma	N/A	-582.23%	-184.20%

In the previous week, Quantum Biopharma had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 7 mentions for Quantum Biopharma and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.62 beat Quantum Biopharma's score of 0.41 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

1.2% of Quantum Biopharma shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Telomir Pharmaceuticals beats Quantum Biopharma on 6 of the 11 factors compared between the two stocks.

How does Quantum Biopharma compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Sera Prognostics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Quantum Biopharma	N/A	-582.23%	-184.20%

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 176.38%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 129.23%. Given Sera Prognostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sera Prognostics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sera Prognostics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 10 mentions for Sera Prognostics and 7 mentions for Quantum Biopharma. Sera Prognostics' average media sentiment score of 0.44 beat Quantum Biopharma's score of 0.41 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum Biopharma has lower revenue, but higher earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$70K	1,121.48	-$31.93M	-$0.67	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Summary

Sera Prognostics beats Quantum Biopharma on 12 of the 15 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.33M	$12.45B	$7.17B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.64	792.11	273.41	25.34
Price / Sales	N/A	763.33	674.93	98.63
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	2.60	10.40	10.38	6.20
Net Income	-$26.17M	$2.83B	$3.49B	$358.18M
7 Day Performance	6.08%	-3.31%	-2.20%	-1.61%
1 Month Performance	-8.16%	0.77%	-0.39%	-3.63%
1 Year Performance	-79.94%	3.62%	19.16%	5.94%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	2.5995 of 5 stars	$3.49 +0.9%	$8.00 +129.2%	-79.9%	$22.33M	N/A	N/A	N/A	News Coverage
OKYO OKYO Pharma	2.7595 of 5 stars	$1.53 -2.5%	$5.67 +270.4%	-34.9%	$82.39M	N/A	N/A	7	High Trading Volume
YARW Yarrow Bioscience	2.4921 of 5 stars	$29.30 -3.0%	$58.00 +98.0%	N/A	$80.65M	$570K	N/A	30	News Coverage Short Interest Increase
CTOR Citius Oncology	2.0244 of 5 stars	$0.93 +8.0%	$6.00 +545.8%	-50.8%	$79.96M	$7.11M	N/A	N/A	Gap Down High Trading Volume
TELO Telomir Pharmaceuticals	0.353 of 5 stars	$1.19 +2.6%	N/A	-14.0%	$79.78M	N/A	N/A	1	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. OKYO, YARW, CTOR, TELO, and SERA

How does Quantum Biopharma compare to OKYO Pharma?

Summary

How does Quantum Biopharma compare to Yarrow Bioscience?

Summary

How does Quantum Biopharma compare to Citius Oncology?

Summary

How does Quantum Biopharma compare to Telomir Pharmaceuticals?

Summary

How does Quantum Biopharma compare to Sera Prognostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. OKYO, YARW, CTOR, TELO, and SERA

How does Quantum Biopharma compare to OKYO Pharma?

Do insiders & institutionals believe in OKYO or QNTM?

Do analysts rate OKYO or QNTM?

Which has better valuation and earnings, OKYO or QNTM?

Does the media prefer OKYO or QNTM?

Is OKYO or QNTM more profitable?

Which has more risk and volatility, OKYO or QNTM?

Summary

How does Quantum Biopharma compare to Yarrow Bioscience?

Do insiders and institutionals hold more shares of YARW or QNTM?

Which has more risk and volatility, YARW or QNTM?

Does the media prefer YARW or QNTM?

Do analysts recommend YARW or QNTM?

Which has preferable valuation & earnings, YARW or QNTM?

Is YARW or QNTM more profitable?

Summary

How does Quantum Biopharma compare to Citius Oncology?

Do insiders & institutionals have more ownership in QNTM or CTOR?

Is QNTM or CTOR more profitable?

Which has more volatility and risk, QNTM or CTOR?

Does the media favor QNTM or CTOR?

Which has higher valuation and earnings, QNTM or CTOR?

Do analysts prefer QNTM or CTOR?

Summary

How does Quantum Biopharma compare to Telomir Pharmaceuticals?

Do analysts prefer TELO or QNTM?

Is TELO or QNTM more profitable?

Does the media favor TELO or QNTM?

Which has more risk and volatility, TELO or QNTM?

Which has stronger earnings & valuation, TELO or QNTM?

Do institutionals and insiders hold more shares of TELO or QNTM?

Summary

How does Quantum Biopharma compare to Sera Prognostics?

Which has more risk & volatility, SERA or QNTM?

Do institutionals and insiders believe in SERA or QNTM?

Is SERA or QNTM more profitable?

Do analysts recommend SERA or QNTM?

Does the media refer more to SERA or QNTM?

Which has preferable earnings & valuation, SERA or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools